EA201792294A1 - Комбинированное лечение (варианты) с применением серибантумаба - Google Patents
Комбинированное лечение (варианты) с применением серибантумабаInfo
- Publication number
- EA201792294A1 EA201792294A1 EA201792294A EA201792294A EA201792294A1 EA 201792294 A1 EA201792294 A1 EA 201792294A1 EA 201792294 A EA201792294 A EA 201792294A EA 201792294 A EA201792294 A EA 201792294A EA 201792294 A1 EA201792294 A1 EA 201792294A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seribantumab
- options
- combined treatment
- cancer
- methods
- Prior art date
Links
- 229950008834 seribantumab Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102000048238 Neuregulin-1 Human genes 0.000 abstract 2
- 108090000556 Neuregulin-1 Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149271P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/027933 WO2016168730A1 (en) | 2015-04-17 | 2016-04-15 | Combination treatments with seribantumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201792294A1 true EA201792294A1 (ru) | 2018-03-30 |
Family
ID=55854801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792294A EA201792294A1 (ru) | 2015-04-17 | 2016-04-15 | Комбинированное лечение (варианты) с применением серибантумаба |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160303232A1 (enExample) |
| EP (1) | EP3283068A1 (enExample) |
| JP (1) | JP2018513155A (enExample) |
| KR (1) | KR20170137886A (enExample) |
| CN (1) | CN107750165A (enExample) |
| AU (1) | AU2016248329A1 (enExample) |
| CA (1) | CA2983008A1 (enExample) |
| EA (1) | EA201792294A1 (enExample) |
| HK (2) | HK1248539A1 (enExample) |
| IL (1) | IL255092A0 (enExample) |
| MA (1) | MA45420A (enExample) |
| SG (1) | SG11201708491PA (enExample) |
| WO (1) | WO2016168730A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017161009A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment |
| WO2018140821A1 (en) * | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| AU2019301633A1 (en) | 2018-07-09 | 2021-01-28 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses |
| JP2023549854A (ja) | 2020-11-16 | 2023-11-29 | スロゼン オペレーティング， インコーポレイテッド | 肝臓特異的Ｗｎｔシグナル増強分子およびその使用 |
| CN115976196B (zh) * | 2022-12-16 | 2024-12-06 | 深圳市人民医院 | ErbB3作为肺动脉高压生物标志物和治疗靶点的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007008768A (es) * | 2005-01-21 | 2007-10-19 | Genentech Inc | Dosificacion fija de anticuerpos her. |
| WO2007001986A2 (en) | 2005-06-20 | 2007-01-04 | Yuling Luo | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations |
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| JP2013522237A (ja) | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| JP6200806B2 (ja) | 2010-05-21 | 2017-09-20 | メリマック ファーマシューティカルズ インコーポレーティッド | 二重特異的融合タンパク質 |
| UY33498A (es) * | 2010-07-09 | 2013-01-03 | Sanofi Aventis | Combinaciones de inhibidores de quinasas para el tratamiento de cancer |
| AU2012211258A1 (en) | 2011-01-27 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-ErbB3 antibodies |
| JP2014508782A (ja) | 2011-03-11 | 2014-04-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 |
| CN103429262A (zh) * | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
| PH12013502663A1 (en) | 2011-06-30 | 2018-03-21 | Merrimack Pharmaceuticals Inc | Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers |
| WO2013023043A2 (en) | 2011-08-10 | 2013-02-14 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy |
| AU2013201584A1 (en) | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| WO2015048793A2 (en) * | 2013-09-30 | 2015-04-02 | Daiichi Sankyo Co., Ltd. | Nucleic acid biomarker and use thereof |
| WO2015100459A2 (en) * | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
-
2016
- 2016-04-15 HK HK18108183.0A patent/HK1248539A1/zh unknown
- 2016-04-15 AU AU2016248329A patent/AU2016248329A1/en not_active Abandoned
- 2016-04-15 HK HK18110002.5A patent/HK1250626A1/zh unknown
- 2016-04-15 EA EA201792294A patent/EA201792294A1/ru unknown
- 2016-04-15 SG SG11201708491PA patent/SG11201708491PA/en unknown
- 2016-04-15 EP EP16718955.4A patent/EP3283068A1/en not_active Withdrawn
- 2016-04-15 JP JP2017553926A patent/JP2018513155A/ja not_active Withdrawn
- 2016-04-15 MA MA045420A patent/MA45420A/fr unknown
- 2016-04-15 WO PCT/US2016/027933 patent/WO2016168730A1/en not_active Ceased
- 2016-04-15 CN CN201680035146.7A patent/CN107750165A/zh active Pending
- 2016-04-15 CA CA2983008A patent/CA2983008A1/en not_active Abandoned
- 2016-04-15 KR KR1020177033074A patent/KR20170137886A/ko not_active Withdrawn
- 2016-05-17 US US15/156,603 patent/US20160303232A1/en not_active Abandoned
-
2017
- 2017-10-17 IL IL255092A patent/IL255092A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170137886A (ko) | 2017-12-13 |
| US20160303232A1 (en) | 2016-10-20 |
| CN107750165A (zh) | 2018-03-02 |
| MA45420A (fr) | 2019-05-01 |
| AU2016248329A1 (en) | 2017-11-09 |
| HK1248539A1 (zh) | 2018-10-19 |
| SG11201708491PA (en) | 2017-11-29 |
| EP3283068A1 (en) | 2018-02-21 |
| HK1250626A1 (zh) | 2019-01-11 |
| JP2018513155A (ja) | 2018-05-24 |
| IL255092A0 (en) | 2017-12-31 |
| CA2983008A1 (en) | 2016-10-20 |
| WO2016168730A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| MX391720B (es) | Terapia combinada para tratar cáncer. | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| BR112017019829A2 (pt) | antagonista do receptor nk-3, para o tratamento terapêutico ou cosmético de gordura corporal em excesso | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| MX2020001727A (es) | Terapia de combinacion. | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| EA201792560A1 (ru) | Наночастицы для применения в качестве терапевтической вакцины | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| EA201892631A1 (ru) | Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico |